These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 21490305)

  • 41. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
    Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
    Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Characteristics of PIK3CA gene mutations in Her2-low breast cancer].
    Pavlenko IA; Povilaitite PE; Makarevich NS; Kaciyaev VY; Petrov AV
    Arkh Patol; 2023; 85(4):5-11. PubMed ID: 37530184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
    André F; Hurvitz S; Fasolo A; Tseng LM; Jerusalem G; Wilks S; O'Regan R; Isaacs C; Toi M; Burris H; He W; Robinson D; Riester M; Taran T; Chen D; Slamon D
    J Clin Oncol; 2016 Jun; 34(18):2115-24. PubMed ID: 27091708
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
    Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
    Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
    López-Knowles E; O'Toole SA; McNeil CM; Millar EK; Qiu MR; Crea P; Daly RJ; Musgrove EA; Sutherland RL
    Int J Cancer; 2010 Mar; 126(5):1121-31. PubMed ID: 19685490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
    Atreya CE; Sangale Z; Xu N; Matli MR; Tikishvili E; Welbourn W; Stone S; Shokat KM; Warren RS
    Cancer Med; 2013 Aug; 2(4):496-506. PubMed ID: 24156022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
    Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
    PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
    Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
    Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.
    Cizkova M; Susini A; Vacher S; Cizeron-Clairac G; Andrieu C; Driouch K; Fourme E; Lidereau R; Bièche I
    Breast Cancer Res; 2012 Feb; 14(1):R28. PubMed ID: 22330809
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    She QB; Gruvberger-Saal SK; Maurer M; Chen Y; Jumppanen M; Su T; Dendy M; Lau YK; Memeo L; Horlings HM; van de Vijver MJ; Isola J; Hibshoosh H; Rosen N; Parsons R; Saal LH
    BMC Cancer; 2016 Aug; 16():587. PubMed ID: 27484095
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
    McCarthy AM; Kumar NP; He W; Regan S; Welch M; Moy B; Iafrate AJ; Chan AT; Bardia A; Armstrong K
    BMC Cancer; 2020 Apr; 20(1):347. PubMed ID: 32326897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PTEN loss is a predictive marker for HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.
    Tekesin K; Emin Gunes M; Bayrak S; Akar E; Ozturk T; Altinay S; Tural D
    J BUON; 2019; 24(5):1920-1926. PubMed ID: 31786856
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
    Loi S; Haibe-Kains B; Majjaj S; Lallemand F; Durbecq V; Larsimont D; Gonzalez-Angulo AM; Pusztai L; Symmans WF; Bardelli A; Ellis P; Tutt AN; Gillett CE; Hennessy BT; Mills GB; Phillips WA; Piccart MJ; Speed TP; McArthur GA; Sotiriou C
    Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10208-13. PubMed ID: 20479250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patients.
    Hayama S; Nakamura R; Ishige T; Sangai T; Sakakibara M; Fujimoto H; Ishigami E; Masuda T; Nakagawa A; Teranaka R; Ota S; Itoga S; Yamamoto N; Nagashima T; Otsuka M
    BMC Cancer; 2023 Apr; 23(1):384. PubMed ID: 37106324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
    BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.
    Banneau G; Guedj M; MacGrogan G; de Mascarel I; Velasco V; Schiappa R; Bonadona V; David A; Dugast C; Gilbert-Dussardier B; Ingster O; Vabres P; Caux F; de Reynies A; Iggo R; Sevenet N; Bonnet F; Longy M
    Breast Cancer Res; 2010; 12(4):R63. PubMed ID: 20712882
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
    Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
    Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
    Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
    Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.